Business
GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations
GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations\nCanada NewsWire\nLAS VEGAS, Dec. 20, 2019\n\n\n\nIn an animal model of the disease, GB Sciences' formulations were able to reduce Parkinson's disease-like behavioral symptoms 'back to baseline' with negligible side effects.\n LAS VEGAS, Dec. 20, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease (\"PD\") formulations from the midterm report for their preclinical study being performed by Dr. Lee Ellis of the National Research Council (NRC) in Halifax, Nova Scotia, CANADA. GB Sciences' PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons, which underlies the pathology of Parkinson's disease in the animal model. Our final phase of testing will study the mechanism of action for these promising formulations, which could potentially help patients with this debilitating disease. The combined direct and indirect costs associated with Parkinson's disease are estimated at $52 billion in the U.S. alone.\n\n \n \n\n \n\"Several of GB Sciences' mixtures were effective. In fact, our most effective mixture was able to 'rescue' the PD-like behavioral changes to the point where the treated animal's behavior was back to baseline. In addition, our PD formulas produced negligible side effects, which is equally important,\" explained Dr. Andrea Small-Howard, Chief Science Officer and Director of both GB Sciences, Inc. and GBS Global Biopharma, Inc. \"These important preclinical results will be included as 'proof of concept' in GB Sciences' Investigational New Drug application with US FDA in order to enter into our 'First-in-Man' human clinical trial as early as next year.\" \nCentral to the development of Parkinson's disease is the loss of dopamine-producing neurons. Reduced dopamine levels in the brain lead...